SCHEMBL557517

SCHEMBL557517

Nc1nccnc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29913086 1.00
SCHEMBL29985108 0.75
SCHEMBL690409 0.75
SCHEMBL1024624 0.75
SCHEMBL29457483 0.65
SCHEMBL274632 0.65
SCHEMBL41047 0.65
SCHEMBL6711366 0.63
SCHEMBL20551999 0.63
SCHEMBL30398249 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107056789-B With substitution pyrazine and imidazole derivative, preparation and its application in medicine 陈剑 2019-03-29 CN claimed
CN-107056789-A With substitution pyrazine and imidazole derivative, it is prepared and its in application pharmaceutically 陈剑 2017-08-18 CN claimed
CN-104496917-A Synthesis method of Favipiravir NANJING HUAWE MEDICAL TECHNOLOGY DEV CO LTD 2015-04-08 CN claimed
EP-4720058-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF Casma Therapeutics, Inc. (US) 2026-04-08 EP disclosed
US-12565496-B2 Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof BAYER AKTIENGESELLSCHAFT (DE) 2026-03-03 US disclosed
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 US disclosed
US-20250332155-A1 SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS AURIGENE ONCOLOGY LTD (IN) 2025-10-30 US disclosed
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2025-10-02 US disclosed
US-12377088-B2 Substituted tetrahydroquinolinone compounds as ROR gamma modulators AURIGENE ONCOLOGY LIMITED (IN) 2025-08-05 US disclosed
US-12365695-B2 Fused ring heteroaryl compounds as RIPK1 inhibitors BISICHEM CO., LTD. (KR) 2025-07-22 US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 US disclosed
CN-1272328-C Pyrazine based inhibitors of glycogen synthase kinase 3 CHIRON CORP (US) 2006-08-30 CN disclosed
WO-2006086545-A2 METHOD TO IDENTIFY NOVEL THERAPEUTICS DESIMONE ROBERT W (US) 2006-08-17 WO disclosed
CN-1668619-A Imidazo [1, 2-a ] pyrazin-8-ylamines, methods of making and methods of use thereof CELLULAR GENOMICS INC (US) 2005-09-14 CN disclosed
CN-1639132-A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases ASTRAZENECA AB (SE) 2005-07-13 CN disclosed
US-20040034225-A1 Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) 2004-02-19 US disclosed
CN-1434807-A Pyrazine based inhibitors of glycogen synthase kinase 3 CHIRON CORP (US) 2003-08-06 CN disclosed
EP-1292580-A1 PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2003-03-19 EP disclosed
WO-2001087853-A1 ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2001-11-22 WO disclosed
JP-2001089460-A PRODUCTION PROCESS FOR 2-AMINOBROMOPIPERAZINES KOEI CHEM CO LTD 2001-04-03 JP disclosed